Over 70 years ago Otto Warburg observed that cancer cells produce excessive lactate in the presence of oxygen, a state he termed 'aerobic glycolysis' [1] [2] [3] . Today, this high rate of glucose uptake by solid tumours is used as a diagnostic through 18 F-2-deoxyglucose (FDG) accumulation detected by positron emission tomography 4 . During the twentieth century considerable effort was expended to determine whether aerobic glycolysis was due to defects in mitochondrial oxidative phosphorylation (OXPHOS), with generally negative results
F-2-deoxyglucose (FDG) accumulation detected by positron emission tomography 4 . During the twentieth century considerable effort was expended to determine whether aerobic glycolysis was due to defects in mitochondrial oxidative phosphorylation (OXPHOS), with generally negative results 5 . However, this failure was more a reflection of a lack of fundamental knowledge about mitochondrial biology than a lack of relevance of mitochondria to cancer.
The mitochondrial bacterium is the 2 billion year symbiotic partner of the nuclear-cytosolic organism 6, 7 . Today, the mitochondrial genome encompasses between one and two thousand nuclear DNA (nDNA) genes plus thousands of copies of mitochondrial DNA (mtDNA) that reside within the mitochondrion. The mtDNA retains the 13 most important OXPHOS genes, while the nDNA contains all of the remaining OXPHOS genes, as well as the genes for mitochondrial metabolism and biogenesis (FIGS 1, 2) . The mitochondrion is a highly evolved system for coordinating energy production and distribution based on the availability of calories and oxygen and the demands for cellular maintenance and reproduction. In many cancer cells, bioenergetic reprogramming involves switching from the maximal ATP production by OXPHOS in quiescent, differentiated cells to the requirement for balancing energy needs with substrate generation for cellular biogenesis and reproduction in rapidly growing cells.
Many vital cellular parameters are controlled by mitochondria. These include regulation of energy production, modulation of oxidation-reduction (redox) status, generation of reactive oxygen species (ROS), control of cytosolic calcium (Ca 2+ ) levels, contribution to cytosolic biosynthetic precursors such as acetyl-CoA and pyrimidines, and initiation of apoptosis through the activation of the mitochondrial permeability transition pore (mtPTP) (FIG. 3) . Changes in these parameters can impinge on biosynthetic pathways, cellular signal transduction pathways, transcription factors and chromatin structure to shift the cell from a quiescent, differentiated state to an actively proliferating one.
Although mutations in the mtDNA in cancer cells have been recognized for more than two decades 8 , interest in the role of mitochondrial alterations in cancer came to general attention with the discovery of mitochondrial tricarboxylic acid (TCA) cycle gene mutations in cancer cells. Cancer cell defects are now well established in the genes for succinate dehydrogenase (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase 1 (IDH1) and IDH2 (FIG. 2) .
Analysis of the pathophysiological consequences of mitochondrial gene mutations is providing broad new insights into the importance and complexity of mitochondrial alterations in cancer. In this Review I discuss these observations in the context of how alterations in mitochondrial function can signal to the nucleus to change its developmental and replicative status ('retrograde signalling') and influence the metabolic status of the surrounding stromal cells (the 'reverse Warburg effect').
Mutations that affect the expression of mtDNA ρ o cells and tumorigenesis. The requirement of cancer cells for functional mitochondria has been confirmed by the elimination of mtDNA from various cancer cells through growth in ethidium bromide (ρ o cells). The resulting ρ o cancer cells have reduced growth rates, decreased colony formation in soft agar and markedly reduced tumour formation in nude mice [9] [10] [11] [12] [13] [14] [15] . The importance of functional mitochondria has been further demonstrated by the transmissible tumours of Tazmanian devils and dogs. These tumours have been transferred from animal to animal for tens of thousands of years 16 and should have died out owing to the decay of their mtDNAs. However, this limitation has been circumvented by the periodic acquisition by tumours of normal mtDNA from host cells 17, 18 . mtDNA mutations and cancer. Somatic and germline mtDNA mutations have been reported for a wide variety of cancers. These include renal adenocarcinoma, colon cancer cells, head and neck tumours, astrocytic tumours, thyroid tumours, breast tumours, ovarian tumours, prostate and bladder cancer, neuroblastomas and oncocytomas [19] [20] [21] [22] [23] [24] . Although technical and interpretive errors were common in early publications on mtDNA mutations in cancer [25] [26] [27] , the identification of clearly deleterious mtDNA mutations in cancer tissues -such as an intragenic deletion 8 or the common tRNA Leu(UUR) A3243G MELAS mutation 26 -validate the relevance of pathogenic mutations in neoplastic transformation. The importance of the mtDNA in cancer has been confirmed by the exchange of cancer cell mtDNA with pathogenic or normal mtDNA, resulting in alterations of cancer cell phenotypes [28] [29] [30] [31] . Ancient mtDNA population variants have also been correlated with cancer risk. For example, the macrohaplogroup N variant in the complex I, subunit ND3 gene (ND3; also known as MTND3) at nucleotide G10398A (resulting in a T114A amino acid change) has been associated with breast cancer risk in African American women 32 , and the 16519 T to C mtDNA control region variant is associated with endometrial cancer 33 . A mtDNA cytochrome c oxidase subunit 1 (CO1; also known as MTCO1) T6777C nucleotide variant has been linked with epithelial ovarian cancer, along with variants in several nDNA mitochondrial genes 34 . Furthermore, the mtDNA control region variant C150 (REF. 35 ) has been associated with an increased risk of human papilloma virus (HPV) infection and cervical cancer in Chinese women 36 .
A meta-analysis of many cancer-associated mtDNA mutations revealed that many cancer cell mtDNA mutations clearly inhibit OXPHOS. However, a significant proportion of the reported variants are the same nucleotide changes that have previously been reported as ancient adaptive mtDNA variants in human populations [37] [38] [39] [40] . Although some of these cancer 'associations' are clear misinterpretations of ancient polymorphisms, others may be valid cancer cell mutations 41 . Consequently, there may be two classes of mutations in cancer cell mtDNA: mutations that impair OXPHOS and serve to stimulate neoplastic transformation, and those that facilitate cancer cell adaption to changing bioenergetic environments 19 . The importance of mtDNA mutations in neoplastic transformation is best illustrated by example. In one prostate tumour a de novo CO1 chain termination mutation was homoplasmic (pure) mutant in the tumour but homoplasmic wild-type in adjacent normal epithelial tissue. This abrupt change in the thousands of copies of mtDNA implies that the CO1 nonsense mutation was under intense positive selection in the cancer cell 29 .
In an oncocytoma, the tumour cells were homoplasmic for an ND5 gene frame-shift mutation, and the normal tissues of the patient and his two sisters harboured the same mutation, but at low frequency (low heteroplasmy). Hence, an ND5 frame-shift mutation transmitted through the maternal lineage at low heteroplasmy switched to high heteroplasmy in the tumour, again demonstrating positive selection for the mutant mtDNA 22 . The mtDNA is condensed into nucleoids through the binding of mitochondrial transcription factor A (TFAM; also known as mtTFA). Some colorectal cancers harbour heterozygous TFAM mutations that are associated with mtDNA depletion 42 . TFAM has also been observed to be translocated into the nucleus in prostate cancer cells, and These metabolic alterations can inhibit various α-ketoglutarate-dependent dioxygenases; they can also activate the NFE2-related factor 2 (NRF2) stress response pathway. All of these effects can contribute to tumorigenesis.
• Activation of signalling pathways and oncogenes that are known to be important in tumorigenesis also affect mitochondrial function. The PI3K-PTEN-AKT pathway shifts metabolism from oxidative to glycolytic, thus permitting the redistribution of glycolytic nutrients from catabolism to anabolism. Activation of MYC induces glutaminolysis, which provides anaplerotic substrates to the mitochondrial tricarboxylic acid cycle, thus enhancing citrate production and its export to the cytosol to provide acetyl-CoA for lipid biogenesis and protein modifications.
• Altered mitochondrial metabolism can increase the production of mitochondrial reactive oxygen species (ROS) and change the cellular redox status, thus altering the activities of transcription factors such as HIF1α and FOS-JUN to change gene expression and stimulate cancer cell proliferation.
• A decrease of the mitochondrial membrane potential or mutation of the promyelocytic leukaemia (PML) gene reduces mitochondrial Ca 2+ uptake, thus decreasing the activation of the mitochondrial intrinsic apoptosis pathway.
• Reduced mitochondrial Ca 2+ retention increases the cytosolic Ca 2+ concentration. This activates mitochondrial retrograde signalling through stimulation of calcineurin and IκBβ-dependent NF-κB, activation of enhanceosome-driven transcription and increased metastatic potential.
• Cancer cell ROS production inactivates caveolin 1 in adjacent stromal fibroblasts.
This increases mitophagy, reduces mitochondrial function and increases lactate production in these fibroblasts. Secreted stromal cell lactate then fuels cancer cell oxidative metabolism, which drives tumour growth and proliferation. This is known as the 'reverse Warburg effect'. Nature Reviews | Cancer Mitochondrion Cytoplasm overexpression of TFAM can stimulate cell proliferation 43 . In addition to TFAM, mtDNA nucleoids harbour multiple additional proteins that are involved in mtDNA replication and transcription 44, 45 , one of which is the nuclearencoded RNA helicase, SUV3 (also known as SUPV3L1). Knockdown of SUV3 results in reduced mtDNA copy number, a shift in mitochondrial morphology, downregulation of OXPHOS enzymes, increased ROS generation, reduced membrane potential and reduced ATP production 46 . Mice heterozygous for a Suv3 null mutation have a reduced lifespan and increased tumour incidence, both of which are associated with increased mtDNA somatic mutation levels and decreased mtDNA copy number. The reduced lifespan and increased tumorigenesis that is evident in a Suv3 +/− mother can be transmitted to her Suv3
(wild-type) daughters. Hence, reduced longevity and cancer predilection are the result of Suv3-induced maternally transmitted mtDNA alterations 47 . Although functional mitochondria and mtDNAs are essential for cancer cell growth and tumori genesis, mtDNA mutations and/or reductions in mtDNA copy number that alter the OXPHOS physiology are common features of cancer. This implies that alterations in mitochondrial bioenergetics and metabolism have a role in initiating and/or sustaining the transformed state.
Mitochondrial enzyme defects in cancer
In addition to mutations that directly affect mtDNA, mutations in nDNA-encoded mitochondrial enzymes have been found in specific cancers. Analysis of the physiological consequences of these mutations is providing insight into how changes in mitochondrial metabolism can reprogramme the nucleus.
SDH mutations.
Homozygous null mutations in the genes of the various SDH subunits have been observed in paragangliomas and pheochromocytomas 48 . SDH (also known as respiratory complex II) is an integral mitochondrial inner membrane protein complex that oxidizes succinate to fumarate and transfers two electrons to coenzyme Q 10 (CoQ) (FIG. 2) . SDH is composed of four subunits: SDHA-SDHD. SDHA contains an FAD cofactor that binds the substrates succinate and fumarate; SDHB contains the iron-sulphur centre electron carriers; and SDHC and SDHD constitute the inner membrane cytochrome b and form the CoQ binding site. The assembly of SDH requires two factors, SDH assembly factor 1 (SDHAF1) and SDHAF2 (REF. 48 ). Initial reports of SDH mutations in paragangliomas involved SDHD 49 , SDHC 50 and SDHB
51
. Subsequent research revealed that cancerous mutations can also occur in SDHA and SDHAF2, with SDH defects accounting for 10-30% of sporadic paragangliomas and 10-70% of familial paragangliomas 48 . Inhibition of SDH increases mitochondrial and cytosolic succinate levels, which inhibits α-ketoglutaratedependent prolyl hydroxylases (PHDs), thus causing stabilization of hypoxia-inducible factor 1α (HIF1α) 52 . The stabilized HIF1α is then translocated into the nucleus 48 and causes a shift in energy metabolism from oxidative to glycolytic 53 . HIF1α may also be stabilized by the inactivation of PHDs by ROS that have been generated by mitochondrial complex III [54] [55] [56] , as SDH-deficient cells have increased mitochondrial ROS production and oxidative stress 48 . Succinate and fumarate also inhibit other α-ketoglutarate-dependent dioxygenases, including the Jumonji-C histone demethylases (JHDMs) and the TET family of 5-methylcytosine hydroxylases, resulting in genome-wide alterations of histone and DNA methylation and epigenetic dysregulation 48, 57 . FH mutation. Homozygous null mutations in the FH gene are associated with multiple cutaneous and uterine leiomyomatas and aggressive forms of renal cell cancer 58 . FH converts fumarate to malate, and cells harbouring FH mutations produce up to 100-fold more fumarate, Figure 1 | Mitochondrial genome and mitochondrial biogenesis. The mitochondrial genome encompasses between one and two thousand nuclear-DNA-encoded mitochondrial genes and thousands of copies of the mitochondrial DNA (mtDNA). mtDNA has a high mutation rate, and de novo mtDNA mutations create a mixture of mutant and normal mtDNAs in cells, a state known as heteroplasmy. As the proportion of mutant mtDNAs increases, the energy output capacity of the cell declines until there is insufficient energy to sustain cellular function, termed the bioenergetic threshold. Mitochondria also constantly undergo fusion and fission, which permits complementation of mtDNAs in trans 7, 53, 84, 108, 168 . The mtDNA encodes 13 proteins, 22 tRNAs, and 12S and 16S rRNAs. The mtDNA is packaged in the nucleoid and is replicated by DNA polymerase-γ (pol-γ). It is transcribed by mitochondrial RNA polymerase (RNA pol) symmetrically from both stands as large polycistron transcripts in which the larger transcripts are punctuated by the tRNAs. Cleavage of the tRNAs out of the polycistron transcripts creates the mature rRNAs and mRNAs, which are then translated on mitochondrial-specific chloramphenicolsensitive ribosomes, in which the polypeptides are initiated by N-formyl methionine. The mtDNA encodes seven (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) of the 45 polypeptides of complex I; cytochrome b from the 11 polypeptides of complex III; three (cytochrome oxidase I (COI), COII and COIII) of the 13 polypeptides of complex IV; and two (ATP6 and ATP8) of the approximately 17 polypeptides of complex V. These proteins are central electron and proton carriers of the proton-transporting complexes and thus form the wiring diagram for oxidative phosphorylation (OXPHOS). All of the remaining mitochondrial proteins, including approximately 80 OXPHOS subunits and all four subunits of the non-proton-pumping complex II, are encoded by nuclear DNA (nDNA). The mRNAs from the nDNA-encoded subunits are translated on cytosolic ribosomes and the proteins are imported into the mitochondrion by transport through the outer (TOM) and inner (TIM) membrane complexes. TFAM, mitochondrial transcription factor A. Nature Reviews | Cancer Fumarate has also been hypothesized to inhibit PHDs and stabilize HIF1α. However, in Fh −/− mice the additional knockout of Hif1a increased, rather than decreased, the formation of renal cysts, which are progenitors of papillary renal cell carcinoma. Assuming that the Fh −/− mouse approximates the situation in human tumours, this implies that the stabilization of HIF1α is not required for FH −/− tumorigenesis 60 . Increased fumarate levels have been found to activate the stress response pathway that is regulated by NFE2-related factor 2 (NRF2; also known as NFE2L2). NRF2 is normally kept at low levels though degradation by the kelch-like ECH-associated protein 1 (KEAP1) and the ubiquitin E3 ligase cullin 3 complex. However, excess fumarate can inactivate KEAP1 through succination of cysteines 151 and 288, thereby stabilizing NRF2. NRF2 binds to the antioxidant response elements (AREs) and turns on nDNA stress-response genes, one of which is haem oxygenase 1 (HMOX1) 60 . The induction of HMOX1 must be important to tumorigenesis because silencing or inhibiting HMOX1 in Fh −/− cells reduces colony-forming capacity 59 . Inactivation of FH would not only increase fumarate and succinate levels but would also increase succinyl-CoA levels. The induction of HMOX1 could reduce the levels of these metabolites as haem biosynthesis involves combining Citrate carbons then pass through the TCA cycle via the enzymes aconitase, isocitrate dehydrogenase (IDH) isoforms (IDH2 or IDH3), α-ketoglutarate dehydrogenase (αKDH), succinyl-CoA synthetase (SCS), succinate dehydrogenase (SDH; also known as complex II), fumarate hydratase (FH) and malate dehydrogenase (MDH). Cancer mutations have been identified in IDH2, SDH, and FH (shown as red ovals). FH defects are associated with induction of the haemoxygenase 1 (HMOX1), which degrades haem. Haem is synthesized by the condensation of succinyl-CoA and glycine by δ-aminolevulinic acid (ALA) synthetase (ALAS) to generate ALA. Succinyl-CoA conversion to succinate generates GTP, which can drive the condensation of OAA and CO 2 to phosphoenolpyruvate (PEP) by mitochondrial PEP carboxykinase (PEPCK-M). PEP can then be exported to the cytosol. NADH is generated by PDH, IDH3, αKDH and MDH, and can be oxidized by the electron transport chain (ETC). The ETC encompasses five multi-subunit complexes I-IV. NADH is oxidized by complex I (NADH dehydrogenase), and electrons from complexes I and II are transferred to coenzyme Q 10 (CoQ), then passed on to complex III (also known as the b-c1 complex), cytochrome c (cytc), complex IV (also known as cytochrome c oxidase (COX)), and finally to O 2 (half a molecule of O 2 per electron pair) to generate H 2 O. As the electrons traverse complexes I, III and V, protons are pumped out across the mitochondrial inner membrane to generate the electrochemical gradient (ΔP = ΔΨ + Δμ H+ ). ΔP is then used by complex V (H + -translocating ATP synthase) to condense ADP and inorganic phosphate (P i ) to ATP. The ADP and ATP are exchanged across the mitochondrial inner membrane by adenine nucleotide translocators (ANTs) 7, 53, 84, 108 . Cancer cell mitochondrial DNA (mtDNA) mutations have been reported in genes for complexes I, III, IV and V (shown as red squares). Hence, many of the mitochondrial gene mutations in cancer are intimately associated with oxidative phosphorylation (OXPHOS) and the redox regulation of reactive oxygen species (ROS). succinyl-CoA with glycine to generate δ-aminolevulinic acid (ALA) by ALA synthetase (ALAS) to initiate porphyrin synthesis. Porphyrins are converted to haem, which is degraded by HMOX1 to result in the production and excretion of bilirubin (FIG. 2) . This raises the question of why might it be beneficial to reduce succinyl-CoA levels? One possibility could be that when succinyl-CoA is converted to succinate by succinyl-CoA synthetase, GTP is generated. GTP hydrolysis is in turn coupled to the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) by mitochondrial PEP carboxykinase (PEPCK-M), and mitochondrial PEP is exported to the cytosol where it can be converted to pyruvate and ATP 61, 62 . If succinyl-CoA were in excess, this reaction could deplete the 2+ concentrations and can initiate apoptosis by the activation of the mitochondrial permeability transition pore (mtPTP). The mtPTP can be activated by a decreased membrane potential, high-energy phosphates (such as ADP), a more-oxidized redox status, and/or increased mitochondrial matrix Ca 2+ and ROS concentrations. Reducing equivalents and acetyl-CoA enter the mitochondrion via pyruvate and fatty acids. Pyruvate is transported through the mitochondrial inner membrane by the pyruvate transporter (PT) 118 , binds to pyruvate dehydrogenase (PDH), which may be membrane-associated, and is oxidatively decarboxylated to produce acetyl-CoA. Inhibition of mitochondrial function results in pyruvate accumulation in the cytosol, where it can be reduced to lactate. Fatty acids are imported into the mitochondrion bound to carnitine. In the cytosol, fatty acids bound to CoA are transferred to carnitine, transported through the outer and inner mitochondrial membranes, and then transferred back to CoA for β-oxidation. The transfer of fatty acyl groups between CoA and carnitine is mediated by the carnitine palmitoyltransferases (not shown). As a by-product of OXPHOS -the substrates and products of which are transported through the outer membrane by the voltage-dependent anion channels (VDACs) -mitochondria generate ROS by the donation of excess electrons from complexes I and III directly to O 2 to generate superoxide anions (O 2 , which is primarily from complex III, is dismutated by Cu/Zn superoxide dismutase (Cu/ZnSOD; also known as SOD1). H 2 O 2 can be reduced to water by glutathione peroxidase using reduced glutathione as an electron donor. Oxidized glutathione is reduced by glutathione reductase using NADPH as a reductant. In the presence of reduced transition metals, H 2 O 2 can be reduced to hydroxyl radicals (
• OH), which are the most reactive ROS. The mtPTP is a protein complex that is thought to include the translocator protein (TSPO; also known as PBR), an unknown inner-membrane channel, adenine nucleotide translocators (ANTs) and the cyclosporine-A-sensitive cyclophilin D (CYPD; also known as PPID), which are regulatory, in association with the BCL-2 pro-and anti-apoptotic family members. When activated, the mtPTP forms a channel between the inner and outer membranes, which short-circuits ΔP. This is associated with the aggregation of BAX and BAD in the mitochondrial outer membrane to form a megachannel. The megachannel releases pro-apoptotic proteins from the intermembrane space into the cytosol to initiate the degradation of the cellular proteins and DNA 7, 53, 84, 108 . AIF, apoptosis-inducing factor; CoA-SH, coenzyme A with a free sulphydryl group; CoQ, coenzyme Q 10 ; ENDOG, mitochondrial endonuclease G; GPX, glutathione peroxidase; LDH, lactate dehydrogenase; OAA, oxaloacetate; SMAC, second mitochondria-derived activator of caspase; TCA, tricarboxylic acid. Modified, with permission, from REF. mitochondrion of OAA that is required for citrate synthesis and lipid biogenesis. Moreover, excess GTP might adversely affect the homeostasis of the mitochondrial nucleotide pool and compromise mtDNA transcription and replication.
IDH1 and IDH2.
Heterozygous missense mutations in the two NADP + -dependent IDH enzymes, cytosolic IDH1 and mitochondrial IDH2, have been observed in gliomas, astrocytomas, chondromas and acute myeloid leukaemia (AML). A third IDH, NAD + -dependent IDH3, is the primary TCA cycle enzyme for decarboxylating isocitrate to α-ketoglutarate (FIG. 2) , yet this enzyme has not been found to be mutated in cancer. In gliomas, the common IDH mutations are IDH1-R132, IDH2-R172 (the analogous amino acid to IDH1-R132) and IDH2-R140. IDH2-R140 is also the most common IDH mutation in AML. Additional rare IDH1 and IDH2 mutations have also been reported [63] [64] [65] . IDHs are homodimer enzymes, and the cancer cell mutations identified to date create a neomorphic function 66 . Like IDH3, IDH1 and IDH2 can oxidatively decarboxylate isocitrate to α-ketoglutarate. However, IDH1 and IDH2 reduce NADP + instead of NAD + , and the NADP + -dependent reaction is reversible because NADPH can provide sufficient energy to drive the reductive carboxylation of α-ketoglutarate to isocitrate (FIG. 4) . However, the neomorphic IDH1-R132 and IDH2-R172 mutants use NADPH to reduce α-ketoglutarate to R(-)-2-hydroxyglutarate ((R)-2HG). As a result, IDH1 and IDH2 mutant cancers produce 10-100-fold increased levels of (R)-2HG 64 , which has been hypothesized to be an 'oncometabolite'. Contrary to expectations, (R)-2HG has been shown to activate PHD1 (also known as EGLN2) and PHD2 (also known as EGLN1) resulting in decreased HIF1α, unlike the S-enantiomer, which inhibits PHD1 and PHD2. Furthermore, in IDH1-R132H-transformed astrocytes, knockdown of HIF1α increases cellular proliferation and cloning in soft agar, indicating that in this context HIF1α may act as a tumour suppressor gene 67 . (R)-2HG is associated with alterations in cellular genomic methylation and transcription patterns and is a potent inhibitor of the α-ketoglutaratedependent Jumonji-C domain histone N ε -lysine demethylases (JMJD2A, JMJD2C and JMJD2D (also known as KDM4D)). Hence, (R)-2HG may act by altering chromatin modifications [67] [68] [69] . As human astrocytes transformed with IDH-R132H exhibit heightened proliferation at confluence after approximately 14 passages 67 , this suggests that (R)-2HG causes a progressive change in the cellular epigenome. In fact, transduction of mutant IDH1 results in a rapid increase in trimethylation of histone H3 at lysine 9 (H3K9me3) and a subsequent increase in DNA CpG island methylation 70 . Excessive CpG island methylation (the CpG island methylator phenotype (CIMP)) is seen in a subset of glioblastomas, and CIMP correlates almost perfectly with IDH1 and IDH2 mutations. Glioblastomas with IDH1 and IDH2 mutations and CIMP exhibit striking changes in gene expression profile, with differential methylation of over 3,000 genes. The target genes showing marked changes include transforming growth factor-β (TGFβ), RAS, epidermal growth factor receptor (EGFR), WNT and genes in angiogensis pathways 71 . As the WNT pathway, among others, has been implicated in the regulation of mitochondrial energy metabolism 72 , such global changes in chromatin structure could accompany alterations in bioenergetics 53, [73] [74] [75] . Indeed, rendering cancer cells mtDNA-deficient (ρ o ) also results in alterations in CpG island methylation patterns 76, 77 . IDH1 and IDH2 mutations may also alter the cellular redox state. Mitochondria produce NADPH by the transfer of reducing equivalents from NADH to NADP + . This reaction is mediated by the mitochondrial inner membrane enzyme nicotinamide nucleotide transhydrogenase (NNT), with the energy differential between NADH at -250 mV and NADPH at -405 mV being supplied by the mitochondrial inner membrane electrochemical potential (FIG. 4) . The importance of the mitochondrial production of NADPH is demonstrated by the multiple metabolic abnormalities that are observed in Nnt −/− mice [78] [79] [80] [81] [82] . Whereas NADH is oxidized to produce energy, NADPH is used as a reductant for biosynthetic reactions, the glutathionebased detoxification of peroxides, and the regulation of thiol-disulphide enzymes and transcription factors 53 . Using NNT-generated NADPH, mitochondrial α-ketoglutarate can be reductively carboxylated to isocitrate by IDH2 (REF. 83 ). Isocitrate can then be converted to citrate by mitochondrial aconitase. Citrate can be exported to the cytosol where it can be converted to isocitrate by cytosolic aconitase and to α-ketoglutarate by IDH1, generating cytosolic NADPH. α-ketoglutarate or glutamate can then be returned to the mitochondrion to complete the cycle 63, 84 (FIG. 4) .
As both the mitochondria and the cytosol require NADPH for antioxidant defences, the flux of NADPH from the mitochondrion to the cytosol must be regulated to retain NADPH when the mitochondrion is under increased oxidative stress. This may be accomplished by the acute sensitivity of the iron-sulphur centre of the mitochondrial aconitase to inactivation by oxidative stress [85] [86] [87] , inactivation of which would stop the cycle and block the export of mitochondrial NADPH (FIG. 4) .
In heterozygous IDH1 and IDH2 cancer cells the altered IDH activity could generate a futile cycle, which wastes NADPH and α-ketoglutarate. The wild-type IDH1 or IDH2 proteins would generate NADPH from the conversion of isocitrate to α-ketoglutarate but then the mutant IDH1 and IDH2 proteins would expend the NADPH to convert α-ketoglutarate to (R)-2HG (FIG. 4) . The resulting decrease in NADPH levels would inhibit glutathione peroxidase, thus increasing H 2 O 2 levels with heightened signalling effects. Decreased NADPH production would also inhibit the thioredoxins and the bifunctional apurinic/apyrimidinic endonuclease 1 (APE1; also known as redox factor 1 (REF1)), thus perturbing the redox status of crucial transcription factors and favouring proliferation and tumorigenesis. Recently, a transgenic mouse has been reported in which an IDH1-R132H allele is expressed in haematopoietic cells. The NAD + , NADP + , NADH and NADPH levels in bone-marrow-derived macrophages of these animals were reported to be unchanged 88 . However, these experiments seem to have been performed on the Jackson Laboratory C57BL/6j background, which is homozygous for deletion of Nnt 78, 82 . Hence, differential effects on the NADPH/NADP + ratio may not have been apparent in this experimental system.
Mitochondrial ROS production and redox biology NADPH is essential for the reduction of mitochondrially generated H 2 O 2 and other peroxides by glutathione and glutathione peroxidases. When mitochondrial ROS production is too high, it is toxic to the cell and can induce apoptosis or necrosis. However, mitochondrial ROS are also important signalling molecules and potent mitogens 84, [89] [90] [91] , so if apoptosis is inhibited increased ROS production can contribute to neoplastic transformation. . This process is mediated by the mitochondrial inner membrane nicotinamide nucleoside transhydrogenase (NNT), which exploits ΔP to provide the additional reducing potential energy. NADH can either be generated within the mitochondrion or can be imported from the cytosol by the aspartate-glutamate and malate-α-ketoglutarate (αKG) shuttle system. Within the mitochondrion, NADPH can be used to reduce glutathione and thus to control mitochondrial reactive oxygen species (ROS) signalling. Alternatively, NADPH can be used to reduce mitochondrial thioredoxin 2 (TRX2), which regulates the thio-disulphide redox state of mitochondrial proteins. However, NADPH can energize the mitochondrial NADP + -dependent isocitrate dehydrogenase 2 (IDH2) to reductively carboxylate αKG to isocitrate. Isocitrate can then be converted to cis-aconitate and then citrate by mitochondrial aconitase. Citrate can be exported across the mitochondrial inner membrane into the cytosol by the citrate carrier where it can be converted to cis-aconitate and isocitrate by cytosolic aconitase. Cytosolic isocitrate can then be oxidatively decarboxylated by cytosolic NADP + -linked IDH1, producing cytosolic NADPH. The resulting αKG or its aminated derivative glutamate can then be recycled back into the mitochondrion. In the cytosol, the NADPH can be used to reduce glutathione for antioxidant defences, or the reducing equivalents can be funnelled through the nuclear-cytosol TRX1 (for which the reduced (SH 2 ) and oxidized (SS) forms are shown) and then through the bifunctional apurinic/apyrimidinic endonuclease 1 (APE1; also known as redox factor 1(REF1)) protein to reduce thiols in cytosolic and nuclear proteins, including the FOS and JUN transcription factors. Oncogenic mutations in IDH1 or IDH2 (shown as the red ovals with the asterisk) can result in a neomorphic function such that the αKG and NADPH generated by the wild-type IDH1 and IDH2 enzymes (shown as blue ovals) is converted to R(-)-2-hydroxyglutarate ((R)-2HG) and NADP + . This would deplete NADPH, thus increasing ROS production and altering the regulation of nuclear transcription factors 53, 84 . AGA, aspartate-glutamate antiporter; GSH, reduced glutathione monomer; GSSG, oxidized glutathione dimer; MαA, malate-αKG antiporter; OAA, oxaloacetate; PEP, phosphoenolpyruvate; PKM, pyruvate kinase isoform M.
NADPH is also essential for the regulation of the protein function through reduction of thiols (-SH) (FIG 4) . For example, when cysteine thiols in the FOS-JUN heterodimer, which constitute an AP-1 transcription factor, are oxidized to sulphenic acids, the affinity of AP-1 for binding sites in target genes is blocked. However, the FOS-JUN sulphenic acids can be reduced by the bifunctional APE1 protein, the reducing equivalents from NADPH being transmitted through the nuclear-cytosolic thioredoxin 1 (TRX1). APE1 also regulates NRF2, nuclear factor-κB (NF-κB), p53, glucocorticoid receptor (GR), oestrogen receptor (ER) and HIF1α by reducing cysteine residues in these proteins that are required for DNA binding [92] [93] [94] [95] . The mitochondrion has its own thioredoxin, TRX2, and also imports APE1, so protein redox regulation is also crucial for mitochondrial function 84, [96] [97] [98] (FIG. 4) .
Mitochondrial ROS production and redox balance are modulated by the mitochondrial inner membrane electrochemical gradient. The mitochondrial H + -translocating ATP synthase (known as ATP synthase or complex V) uses the proton gradient to produce ATP from ADP and inorganic phosphate (P i ) (FIGS 2,3) . Inhibition of the ATP synthase by oligomycin results in the maximization of the mitochondrial inner membrane polarization, which stalls the electron transport chain (ETC) and reduces the electron carriers in complexes I and III and CoQ. The excess electrons can then be transferred directly to O 2 to generate superoxide (O 2
•−
). Mitochondrial matrix superoxide can be dismutated into H 2 O 2 by Mn superoxide dismutase (MnSOD; encoded by SOD2) while intermembrane-space O 2
•− , which is primarily generated by complex III 15, 99 , is dismutated by intermembrane and cytosolic Cu/ZnSOD (also known as SOD1) (FIG. 3) . H 2 O 2 at increased levels then functions as a diffusible signalling molecule 53, 84 . Inhibition of the ATP synthase has been observed in various carcinomas. This can result from increased levels of the ATP synthase inhibitor protein IF1 100 or inhibition of the transcription or translation of the ATP synthase catalytic β-subunit 5, 101 . Knockdown of the increased levels of IF1 in carcinomas results in a decline in glycolysis and an increase in OXPHOS 100 . As observed with oligo mycin, inhibition of the ATP synthase increases the mitochondrial membrane potential, stalls the ETC and increases ROS production.
Alterations in bioenergetic metabolism in cancer
The PI3K pathway. The shift from oxidative to more glycolytic metabolism commonly involves activation of the PI3K-PTEN-AKT signal transduction pathway, which is one of the most common changes found in cancer 102 . PI3K-PTEN-AKT pathway activation increases the cell surface expression of transporters for glucose and other nutrients, enhances the expression of glycolytic and lipogenesis genes, stimulates hexokinase and phosphofructokinase to drive glycolysis, and activates mTOR. Consistent with the importance of the PI3K-PTEN-AKT pathway in cancer, cancer cells use not only high levels of glucose but also convert over 90% of the resulting pyruvate into lactate by lactate dehydrogenase A (LDHA) 102, 103 .
The PI3K-PTEN-AKT pathway also inhibits expression of carnitine palmitoyltransferase IA, the rate limiting step for fatty acid oxidation 104 , and phosphorylates hexokinase II, enabling it to bind to the mitochondrial outer membrane voltage-dependent anion channel (VDAC; also known as porin) (FIG. 3) . There, hexokinase II captures mitochondrial ATP and uses it to phosphorylate glucose to glucose-6-phosphate, thus driving carbon flow into glycolysis or the pentose phosphate pathway 105, 106 . In Caenorhabditis elegans, insulin-like ligands bind to the DAF-2 receptor (the insulin and insulin-like growth factor 1 receptor analogue), which activates AKT. AKT phosphorylates DAF-16 (the FOXO analogue), resulting in the exclusion of DAF-16 from the nucleus. Inactivation of DAF-2 permits DAF-16 to enter the nucleus and upregulate antioxidant and stress defences, thus extending lifespan 107, 108 . In mammals, there are four FOXO proteins (FOXO1 (also known as FKBR), FOXO3A, FOXO4 and FOXO6) that bind to insulin-response elements (IREs). The mitochondrial transcriptional co-activator, peroxisome proliferation-activated receptor-γ (PPARγ)-co-activator 1α (PGC1α; encoded by PPARGC1A), has three IREs. These are bound by unphosphorylated FOXO1 and this increases PPARGC1A transcription 53, 109 . Expression of PGC1α induces many nDNA-encoded mitochondrial genes, including those for OXPHOS and antioxidant defences 110 . Therefore, activation of the PI3K-PTEN-AKT pathway should remove the FOXOs from the nucleus and downregulate mitochondrial function and antioxidant defences. However, overexpression of FOXO3A has been reported to downregulate mitochondrial function 111 . This occurs through the induction of MAX-interacting protein 1 (MXI1), which inhibits the transcriptional activity of MYC by binding the MYC partner protein MAX. As MYC can induce mitochondrial biogenesis by promoting the transcription of relevant genes 112 , FOXO3A activation must decrease mitochondrial OXPHOS. FOXO3A has also been shown to induce SOD2, which can decrease mitochondrial ROS production. Furthermore, FOXO3A lowered ROS levels in the presence of hypoxia and prevented the stabilization of HIF1α 111 . As HIF1 can repress mitochondrial biogenesis, its degradation would be expected to increase mitochondrial biogenesis. Hence, the bioenergetic effects of FOXO inactivation are complex and must be context-specific.
Although glycolysis can rapidly produce ATP under low oxygen tension, it is also important for generating the precursors and reducing equivalents for cellular biogenesis and antioxidant defences 102 . In glycolysis, pyruvate kinase (PK), which converts PEP to pyruvate, is the ratelimiting step for pyruvate synthesis. In cancer cells it is frequently argued that the common tissue isoform PKM1 is switched to PKM2. However, a recent proteomic analysis concluded that both PKM1 and PKM2 are expressed in normal and cancerous tissues, and that PKM2 is consistently the predominant isoform 113 . PKM2 can be inhibited by Tyr105 phosphorylation by various tyrosine kinases including fibroblast growth factor receptor type 1. Phosphorylation disrupts the active tetramer form, thus releasing the cofactor fructose-1,6-bisphosphate 114 . PKM2 can also be inhibited by oxidative stress through modification of Cys358 (REF. 115 ). Inhibition of PKM2 redirects carbon from oxidation to the anabolic pathways that emanate from glucose-6-phosphate. These include the pentose phosphate pathway, which generates both ribose-5-phosphate for nucleotide synthesis and NADPH for redox control, and glycolysis, which generates glycerol-3-phosphate for lipid synthesis 116 . When oxidative stress is low, PKM2 is active and glucose is metabolized to pyruvate and lactate to generate ATP, but when oxidative stress is high PMK2 is inactive and glucose-6-phosphate is shunted into the pentose phosphate pathway to generate NADPH for antioxidant defences 117 .
Acetyl-CoA regulation. Mitochondrial and cytosolic acetyl-CoA can be hydrolysed by the mitochondria to generate ATP. Acetyl-CoA is also required for cytosolic lipid synthesis 104 and is the co-reactant in the acetylation of proteins that modulate the signal transduction pathways and epigenome 53 . Much of the cellular acetylCoA is generated within the mitochondrion from pyruvate and fatty acid oxidation. Cytosolic pyruvate is imported into the mitochondrion by the pyruvate carrier 118 and converted to acetyl-CoA by mitochondrial pyruvate dehydrogenase (PDH). PDH is inactivated through phosphorylation by PDH kinase (PDHK) and is reactivated by PDH phosphatases. When reducing equivalents in the ETC are limited, the mitochondrial inter membrane space contains a signalosome complex encompassing protein kinase Cδ (PKCδ), retinol, cytochrome c and p66
SHC that increases acetyl-CoA flux into the mitochondrion from pyruvate by inhibiting PDHK2 (REF. 119 ).
Acetyl-CoA is also generated within the mitochondrion by the oxidation of fatty acids. Fatty acyl-CoA molecules are imported into the mitochondrion via carnitine: the transfer from CoA to carnitine is mediated by carnitine palmitoyltransferases. The carnitine palmitoyltransferase isoform 1C is upregulated in lung cancer, indicating the importance of mitochondrial energy and precursor production for this type of cancer cell 120 . Cytosolic acetyl-CoA is essential for fatty acid biogenesis. One important source of cytosolic acetylCoA is the export from the mitochondrion of citrate. In the cytosol citrate is then cleaved by the cytosolic ATP-dependent lyase to OAA and acetyl-CoA 104 . The acetyl-CoA can then be used to synthesize fatty acids, sphingomyelin, cholesterol and isoprenoids 102, 119, 121 , and can also be used in other acetylation reactions.
MYC and glutaminolysis.
Citrate production requires not only acetyl-CoA but also OAA. However, the appropriation of citrate for macromolecular synthesis depletes mitochondrial OAA, thus impeding the TCA cycle. This deficiency can be compensated by the expression of the MYC oncogene, which induces glutaminolysis to feed α-ketoglutarate into the TCA cycle to regenerate OAA, a process known as anaplerosis 121 . Increased expression levels of MYC are seen in many aggressive tumours and have been found to upregulate mitochondrial oxygen consumption and mitochondrial biogenesis. This is associated with transcriptional induction of TFAM, as well as the genes for subunits of complex I, uncoupling proteins, mitochondrial membrane proteins and genes involved in intermediary metabolism 112 . MYC upregulation of mitochondrial function is associated with induction of glutaminase, which converts glutamine to glutamate. MYC also inhibits the expression of the microRNAs miR-23a and miR-23b, which are translational inhibitors of glutaminase. Glutamate is converted to α-ketoglutarate by mitochondrial glutamate dehydrogenase, and α-ketoglutarate progresses around the TCA cycle to OAA 103, 121, 122 . Hence, MYC activation of mitochondrial function and glutaminolysis renders cancer cells glutamine-dependent 122 . p53 and mitochondria. The tumour suppressor p53 (encoded by TP53) can mediate growth arrest and initiate apoptosis 102 . However, it can also be phosphorylated by AMP-activated protein kinase (AMPK) in response to energy limitation, thus activating cell cycle checkpoints. p53 also favours ATP production by OXPHOS and the decrease of cellular ROS production by inducing TP53-induced glycolysis and apoptosis regulator (TIGAR). TIGAR negatively regulates glycolysis by degrading fructose-2,6-bisphosphate, which is an allosteric activator of phosphofructokinase 1 (REF. 102 ). This shifts carbon flux away from glycolysis and into the pentose phosphate pathway, which increases NADPH production and thus heightens antioxidant defences 123, 124 . p53 also negatively regulates phosphoglycerate mutase and AKT, thus further inhibiting glycolysis and upregulating OXPHOS complex IV by the induction of the cytochrome c oxidase (COX) Cu 2+ chaperone, SCO2 (REF. 125 ). Because the inhibition of glycolysis can redirect glucose-6-phosphate into the pentose phosphate pathway, this could increase antioxidant defences in conjunction with increased OXPHOS. Thus, the inactivation of p53 should decrease OXPHOS in favour of glycolysis, increase ROS production and inhibit apoptosis.
In other contexts, p53 activation can also induce cellular senescence. Excessive shortening of chromosomal telomeres activates p53, which then inhibits the transcription of PGC1α and PGC1β. This results in diminished mitochondrial function, increased ROS levels and senescence 126 .
HIF and mitochondria. The transcription factor HIF1 induces glycolysis under low oxygen tension through the upregulation of genes encoding glucose transporters, glycolytic proteins and angiogenic factors (such as erythropoietin and vascular endothelial growth factor (VEGF)), and the inhibition of mitochondrial function. HIF1 affects mitochondria by various mechanisms: it induces PDHK1, thus inhibiting PDH and retarding the conversion of pyruvate to mitochondrial acetylCoA; it induces the low oxygen tension subunit of complex IV, COX4-2; it upregulates the mitochondrial LON protease to degrade the normoxic subunit, COX4-1; it activates mitophagy to degrade existing mitochondria; and it inhibits MYC signalling [127] [128] [129] [130] [131] . HIF1 also upregulates the transcription of miR-210, which downregulates mitochondrial metabolism by inhibiting expression of the ISCU1 and ISCU2 genes -which encode proteins involved in iron sulphur centre synthesis -and genes for subunits of complex I (NDUFA4), complex II (SDHD) and complex IV (COX10) 132 . Mitochondria also regulate HIF1. Mitochondrial ROS from complex III has been shown to inactivate PHD2 and thus to stabilize HIF1α 54, 99 . Mitochondrial sirtuin 3 (SIRT3) also modulates HIF1α through mitochondrially generated ROS 133 . Additionally, mitochondria can stabilize HIF1α through the action of the coiled-coil-helix-coiled-coil-helix (CHCH) domain protein CHCHD4 isoforms, which are part of the mitochondrial protein disulphide relay system involving cytochrome c and complex IV 134 . Finally, HIF1 mediates the transcription of PKM2, but not PKM1, and PKM2 also serves as a co-transcriptional activator of HIF1. This is mediated by PHD3, which hydroxylates prolines 403 and 408 of PKM2, thus enhancing the binding of PKM2 to HIF1α 135, 136 .
Calcium, mitochondria and apoptosis. Mitochondrial physiology is strongly regulated by Ca 2+ (REFS 137,138).
Mitochondria import Ca
2+ through the Ca 2+ uniporter, which is energized by an electrochemical gradient. Mitochondrially associated endoplasmic reticulum membranes (MAMs) bring the endoplasmic reticulum type 3 inositol triphosphate receptor (IP3R) Ca 2+ release channels into juxtaposition with the mitochondrial Ca 2+ uniporter [139] [140] [141] . The promyelocytic leukaemia (PML) protein resides in MAMs, and its inactivation leads to the AKT-mediated hyperphosphorylation of the IP3R3 channels and reduced Ca 2+ flux 141 . Because excessive Ca 2+ uptake by mitochondria can activate the mtPTP and initiate apoptosis [142] [143] [144] , inactivation of PML may limit apoptosis and increase cancer cell survival.
Mitochondrial retrograde signalling
As mitochondrial gene mutations are common in cancer, but mtDNA-encoded OXPHOS genes are essential for cancer cell survival and growth, mutations in mitochondrial genes must therefore be altering cellular bioenergetics and metabolism in ways that are important for neoplastic transformation. For SDH defects this involves the activation of HIF1 signalling; for FH defects, alteration of NRF2 signalling; for IDH1 and IDH2 mutations, alteration of redox signalling; and for all four genes, alteration of chromatin methylation and of the epigenome. Thus, mitochondrial cancer mutations must serve to reprogramme the nucleus, a process called retrograde signalling.
The importance of retrograde signalling has been clearly demonstrated for changes in mitochondrial Ca activates calcineurin, which activates IκBβ-dependent NF-κB to cause the nuclear translocation of the REL-p50 heterodimer. REL-p50 then associates with C/EBPδ, CREB and NFAT in a nuclear enhanceosome 146 . Calcineurin also activates insulin-like growth factor 1 receptor (IGF1R), which acts through PI3K to activate AKT. Phospho-AKT enters the nucleus where it phosphorylates and activates heterogeneous nuclear ribonucleoprotein A2 (HNRNPA2), which acts as a transcriptional co-activator of the enhanceosome. These changes result in the transcriptional upregulation of over 120 nDNA genes. Notably, affected genes include those for maintaining Ca 2+ regulation and homeostasis (such as ryanodine receptor 1 (RYR1), calsequestrin and calreticulin), glucose metabolism (such as IGF1R, insulin receptor substrate 1 (IRS1), GLUT4 and hexokinase), apoptosis (such as AKT1, PI3K, BCL-X S , BID, BAD and BAX), and tissue invasiveness and tumorigenesis (such as cathepsin L, AKT1, transforming growth factor-β (TGFβ), p53 and mouse melanoma antigen) [147] [148] [149] [150] . The importance of ROS and redox signalling in cancer has been demonstrated for HIF1α stabilization 54 , FOS-JUN activation 93 , and activation of proliferation through regulation of the ERK1 and ERK2 MAPK pathway 15 . Direct evidence that mitochondrial ROS are important in neoplastic transformation has come from the analysis of mtDNA mutations found in cultured cancer cells. For example, analyses of mtDNA in mouse L cells has shown that each cell harbours a functional mtDNA mutation and that these mutated mtDNAs increase mitochondrial ROS production and cellular proliferation 151 . The mtDNA mutation ATP6 T8993G -which is found in patients with neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) and Leigh syndrome -results in increased ROS production and tumorigenicity when expressed in the prostate cancer cell line PC3 and HeLa cells. The growth stimulation of the ATP6 mutation can be inhibited by targeting normal ATP6 protein into the mutant mitochondria through allotropic gene expression 29, 30 . A human cell line with an ND5 frameshift mutation and low ROS production had low tumorigenicity, but when the frameshift mtDNA was mixed with wildtype mtDNA ROS production and tumorigenicity increased 152 . Over 30 years ago, it was observed that the fusion of a nontumorigenic hamster cytoplast (an enucleated cell) with a more cancerous hamster cell could partially suppress tumorigenicity 28 . Cytoplasts harbouring mtDNAs with either an ND6 missense or frameshift mutation produce high ROS levels in association with high tumorigenicity when fused with cells with low tumorigenicity, indicating that the constituent mitochondria can transfer these tumorigenic traits. The high tumorigenicity of the original tumour cells and their derived cytoplasmic hybrids (cybrids) is associated with increased HIF1α and MCL1 expression 31 . KRAS-transformed cells produce increased ROS from mitochondrial complex III and this is required for maintaining anchorageindependent growth. These effects of KRAS are inhibited in ρ o cells, in cells in which TFAM has been knocked down, and in cells treated with mitochondrially targeted antioxidants, all of which inhibit mitochondrial ROS production. Carbon flow through glycolysis is also diminished in these cells, which redirect the carbon into the pentose phosphate pathway to generate NADPH and ribose 15 . Although ROS are required for anchorage-independent growth, it follows that chronically increased mitochondrial ROS levels would severely damage mitochondria and mtDNAs. Perhaps to compensate for this effect, RAStransformed cancer cells are addicted to autophagy, and inhibition of this function results in a decline of mitochondrial function 153 . Proof of the importance of mitochondrial ROS production comes from the suppression of tumorigenesis by the genetic introduction of a mitochondrially targeted catalase (mCAT) into mice harbouring the polyoma middle T oncoprotein 154 156 . Hence, removal of mitochondrial H 2 O 2 can inhibit nDNA-oncogene-induced tumorigenesis.
The reverse Warburg effect From the discussions above, it is clear that different types of tumours undergo different bioenergetic adjustments; tumours do not consistently inhibit mitochondrial bioenergetics as suggested by Warburg. Indeed, one study of the energy budget of various cancer cells under normoxic conditions concluded that most of the ATP in cancer cells comes from mitochondria, as is true for normal cells 157 . If this is the case, then why can cancers be detected using FDG accumulation 4 ? The answer may lie with the interaction between the tumour cells and the adjacent stromal cells.
It has been observed that stromal fibroblasts that are associated with breast cancer epithelial cells are glycolytic. The conversion of these fibroblasts from oxidative to glycolytic metabolism is induced by the H 2 O 2 that is secreted from the adjacent cancer cells 158 . This results in loss of caveolin 1 from the fibroblasts, and this in turn causes induction of mitophagy. Mitophagy reduces the number of mitochondria in the stromal fibroblasts, thus reducing mitochondrial function and switching the fibroblast metabolism over to glycolysis. The increased glycolysis due to mitochondrial turnover generates excessive stromal cell lactate and ketones, which are secreted into the intracellular space. The cancer cells then take up the lactate and ketones and use them to feed cancer cell mitochondrial energy production and to generate mitochondrial precursors for cancer cell biogenesis. This metabolic coupling between breast cancer epithelial cells and the stromal fibroblasts renders much of the surrounding tissue glycolytic, which would enhance an FDG signal. This intercellular cooperation has been designated 'stromal-epithelial metabolic coupling' or the 'reverse Warburg effect' and is analogous to the 'neuron-glia metabolic coupling' that is seen in normal brain tissue and in brain tissue from patients with Alzheimer's disease [158] [159] [160] [161] [162] .
Conclusion
The findings discussed throughout this Review indicate that mitochondrial function is essential for cancer cells. However, different cancer cell types undergo different bioenergetic alterations, some to more glycolytic and others to more oxidative, depending in part on the developmental state of the cell undergoing neoplastic transformation. This tissue-specific contextual basis of cancer precludes there being a single bioenergetic transition that is common to all cancer cell types as proposed by Warburg. The resulting diversity probably explains why HIF1α can either be a tumour promoter or suppressor, FOXO and MYC can either increase or decrease mitochondrial biogenesis, and p53 can either enhance or inhibit OXPHOS in cancer. A primary reason for this somewhat confusing picture could be our lack of knowledge of basic mitochondrial biology and genetics, investigations that have been severely constrained over the past 30 years. As a result, our understanding is quite immature regarding various aspects of mitochondrial biology. These include: the cataloguing of proteins that reside in mitochondria 163 ; the regulation of the nuclear-coded mitochondrial genes and the relation of bioenergetics to the epigenome 53 ; the mechanisms by which mitochondrial redox and Ca 2+ are regulated and their effect on the nucleus and cytosol 53, 84 ; the characterization of mitochondrial biogenesis within the mitochondrion 164 ; the consequences of mtDNA heteroplasmy and mtDNA-nDNA interactions 108 ; the definition of systems for tissue-specific bioenergetic regulation 53, 84, 165 ; and the elucidation of the interactions between the cancer cell and the stromal tissue milieu [158] [159] [160] [161] [162] . Progress in all of these areas will require moving cancer studies from isolated cancer cells and tumours into genetically engineered animals in which intercellular interactions can be explored. This will necessitate the introduction of a wide range of mitochondrial gene mutations, particularly mtDNA mutations, into mice 47, 166, 167 . Using such mice, different combinations of mtDNA mutations and nuclear oncogene and tumour suppressor mutations can be generated and studied. Therefore, to move forward we must expand our understanding of the biology and genetics of mitochondria, the neglected cellular symbiont that is so central to our cells, our health and our lives 37 .
